Thank you for your interest in the Janssen CVM IIS Program. The portal is not yet active for submission. Please contact your local MSL to discuss the 2018 Areas of Interest and/or submit your concept. All concepts received by 31 March 2018 will be reviewed in early Q2 2018.

This website is provided to facilitate the submission of Investigator Initiated Study (IIS) proposals for consideration to the Janssen Scientific Affairs, LLC department. This site can only accept proposals from United States based Health Care Professionals and for studies that will be conducted in the US.

Submission of a study concept does not constitute approval. Janssen Scientific Affairs, LLC reserves the right to decline your proposal after concept submission. Upon review by Janssen Scientific Affairs, LLC, the submitter will be notified as to whether the concept has been approved or denied.

If you need further guidance, please contact us at

Investigator Initiated Study Submission Site

Janssen Scientific Affairs, LLC's vision is to lead advances in cardiovascular and metabolic therapeutic areas while enhancing the understanding of our products to improve patient health and quality of life. With our partners, we will conduct innovative research and share knowledge. We will establish ourselves as scientific leaders in cardiovascular thrombosis and metabolics, while modeling integrity and ethics. Janssen Scientific Affairs strives to be a leader in these fields by supporting relevant, innovative, and quality research concepts that enhance the understanding of our products and improve patient lives. We are committed to supporting research concepts that are aligned with our vision and our areas of interest:


  • Clinical studies to evaluate renal physiology associated with SGLT2i mode of action with emphasis on Chronic Kidney Disease.
  • Clinical studies to evaluate the role of SGLT2i in Cardiovascular Disease with emphasis on Heart Failure.
  • Other scientific research related to SGLT2i inhibition may be considered.
  • Clinical studies preferred; preclinical studies by exception only.


  • Studies that address CAD/PAD and HF
  • Studies to evaluate rivaroxaban for the treatment and secondary prevention of cancer associated thrombosis